We thank K. Kavanagh and U. Oppermann for providing the human FPPS expression system, Johan Wouters for providing the human IPPI expression system, H. Sagami for providing the human GGPPS expression system, and M. Kawamukai for providing the human DPPS expression system. This work was supported by the United States Public Health Service (NIH grants GM065307, GM073216, CA113874, AR045504, and AI057160). Y.Z. was supported by a postdoctoral fellowship from the American Heart Association, Midwest Affiliate.
Lipophilic Pyridinium Bisphosphonates: Potent γδ T Cell Stimulators†
Article first published online: 28 DEC 2009
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 49, Issue 6, pages 1136–1138, February 1, 2010
How to Cite
Zhang, Y., Cao, R., Yin, F., Lin, F.-Y., Wang, H., Krysiak, K., No, J.-H., Mukkamala, D., Houlihan, K., Li, J., Morita, Craig T. and Oldfield, E. (2010), Lipophilic Pyridinium Bisphosphonates: Potent γδ T Cell Stimulators. Angew. Chem. Int. Ed., 49: 1136–1138. doi: 10.1002/anie.200905933
- Issue published online: 26 JAN 2010
- Article first published online: 28 DEC 2009
- Manuscript Received: 22 OCT 2009
- NIH. Grant Numbers: GM065307, GM073216, CA113874, AR045504, AI057160
Chain gang: Lipophilic pyridinium bisphosphonates containing long alkyl chains (see picture, P red, N blue, C orange, H gray) stimulate human γδ T cells expressing the Vγ2Vδ2 T cell receptor. Stimulation with such compounds is more potent than with zoledronate, which is active against breast and prostate cancer. The lipophilic bisphosphonates bind poorly to bone and are thus less likely to cause side effects associated with bisphosphonates in clinical use.